Back to search results

Ritual Synbiotic+ for Gastrointestinal Health in Women

This study is testing a dietary supplement called Ritual Synbiotic+, which contains prebiotics, probiotics (Lactobacillus rhamnosus LGG and Bifidibacterium animalis subsp. lactis BB-12), and postbiotics. It aims to see how this supplement affects digestive health, mood, and behavior in women. You may be able to join if you are a healthy woman between 25 and 65 years old, have a Body Mass Index (BMI) less than 30, and experience moderate gastrointestinal symptoms. The study will look at changes in your stool, including short chain fatty acid levels and pH, to see if the supplement is effective. The study is currently recruiting about 60 participants.

Study design
This is a double-blinded, randomized study, meaning neither you nor the researchers will know if you are receiving Ritual Synbiotic+ or a placebo. Around 60 women will participate.
What's involved
You will need to follow the study protocol and attend clinic visits. Stool samples will be collected at baseline, 3 days, 6 weeks, and 12 weeks.
Compensation
Participants will be compensated for their participation.
Follow-up
Your progress will be monitored for 12 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06834984

Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women

Completed
NAAges 25–65InterventionalSupportive care
Colorado State University
~103 participants
Updated 2026-09-10 on ClinicalTrials.gov
What's tested:Prebiotic, probiotic, postbiotic combinationPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Gastrointestinal Symptom Rating Scale
Measured over 4X: baseline, acute (3 days), mid-point (6 weeks), final (12 weeks).
+4 more outcomes measured

Conditions

Gastrointestinal Disease Symptoms

Explore related trials

Gastrointestinal symptom

NCT06834984

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Colorado State University Food and Nutrition Clinical Research Laboratory

    Fort Collins, Coloradono site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Healthy adult women (age 25-65, with target average age of 50).
BMI \<30.
with moderate gastrointestinal symptoms.
Participants should be willing to follow the study protocol and attend clinic visits.

Exclusion

less than 25 years of age or greater than 65 years of age.
have a BMI \>30.
taken antibiotics within two months or any probiotic supplements within the past 14 days prior to the start of treatment.
current medications and dietary supplements will be assessed on a case-by- case basis and will result in exclusion if there is the possibility that the drugs or supplements used would influence the endpoints of the study. This would include statins, metformin, NSAIDs, MAO inhibitors, and hormone therapies.
Individuals with current disease diagnosis, including diagnosis of cancer, liver or kidney disease, gastrointestinal diseases, and cardiometabolic disorders (cardiovascular disease, diabetes, etc.)
pregnant and breastfeeding people.
overuse of alcohol as determined on a case-by-case self-reported alcohol use.
if the individual feels they are unable to adhere to the study requirements, which includes consuming capsules, providing stool or blood samples, tracking bowel movements and symptoms, and attending scheduled clinic visits.

What this trial measures

  • Gastrointestinal Symptom Rating Scale4X: baseline, acute (3 days), mid-point (6 weeks), final (12 weeks).

    Measures Abdominal Pain Heartburn Acid Regurgitation Sucking Sensations in the Epigastrium Nausea \& Vomiting Borborygmus (rumbling) Abdominal Distension (bloating) Eructation (burping) Flatus (gas) Decreased or Increased Passage of Stools Loose or Hard Stools Urgent Need for Defecation Feeling of Incomplete Evacuation Rated on a scale starting at "No Discomfort at all" to "Very severe discomfort", where better outcomes are associated with "No Discomfort At All" while worse outcomes are associated near(er) to "Very Severe Discomfort".

  • Total number and types of bowel movementsDaily for 12 weeks

    Defecation frequency and proportion of abnormal to normal bowel movements as recorded in a diary using the Bristol Stool Form Scale. The scale runs from 1-7 with healthier outcomes associated with 3-5 on the Bristol scale.

  • Short Chain Fatty Acid concentration in stool4X: baseline, acute (3 days), mid-point (6 weeks), final (12 weeks).

    Gas chromatography will be used to measure changes in SCFA production in stool.

  • Fecal pH4X: baseline, acute (3 days), mid-point (6 weeks), final (12 weeks).

    Stool sample pH will be measured before and after treatment.

  • Microbial composition (alpha and beta diversity, dysbiosis index, differential taxa)2X: baseline, and final (12 weeks)

    Changes in microbiota profiles, ratio of pro-inflammatory to beneficial microbes, recovery of LGG \& BB-12 in stool; measured using 16s rRNA and targeted assays.